Outset Medical(US:OM) Globenewswire·2026-01-12 13:30Core Insights - Outset Medical, Inc. reported unaudited revenue for Q4 and fiscal year 2025, highlighting a 5% increase in annual revenue to approximately $119.5 million compared to $113.7 million in 2024 [8] - The company has appointed Karen N. Prange to its board of directors, bringing extensive experience in commercial operations and strategy [4][5][6] - Outset Medical aims to leverage its innovative technology to enhance patient care outcomes while reducing costs and complexity in dialysis [3] Financial Performance - Q4 revenue reached approximately $28.9 million, contributing to the total revenue of approximately $119.5 million for 2025 [8] - The year-end cash position, including restricted cash and short-term investments, totaled $173 million, with net cash used in operations below $50 million in 2025, a significant decrease from $116 million in 2024 [8] Company Developments - Outset Medical has established a strong backlog and a growing pipeline of opportunities as it enters 2026 [3] - The company has enabled over 1,000 care sites to insource dialysis, performing roughly 1 million treatments annually, with a cumulative total of over 3 million treatments on its Tablo system [8] - The appointment of Karen Prange is expected to enhance the board's capabilities in navigating growth opportunities in the acute-care setting [6]